학술논문
Production of the state of the art therapeutic radiopharmaceuticals in Iran, from beta- to alpha-emitting targeted radionuclide therapy: Clinical advances and perspectives.
Document Type
Article
Source
Subject
*CASTRATION-resistant prostate cancer
*PROSTATE cancer
*RADIOISOTOPES
*PROSTATE-specific membrane antigen
*RADIOPHARMACEUTICALS
*LINEAR energy transfer
*MEDICAL personnel
*
*
*
*
*
*
Language
ISSN
1681-2824
Abstract
This article discusses the production of therapeutic radiopharmaceuticals in Iran, specifically focusing on the transition from beta-emitting to alpha-emitting targeted radionuclide therapy (TRT). Iran has made significant advancements in producing diagnostic and therapeutic radiopharmaceuticals, with over 210 nuclear medicine centers and a strong foundation of human resources in the field. The recent manufacturing of alpha-emitting radiopharmaceuticals in Iran has shown promising prospects for TRT, particularly in the treatment of neuroendocrine tumors and metastatic prostate cancer. The use of alpha emitters in cancer treatment has gained interest due to their high radiotoxicity, but it requires specific measures for imaging, dosimetry, and radiation protection. Overall, alpha-emitting radionuclide therapy has the potential to become a significant strategy in cancer management. The document also provides a list of references to various scientific articles related to alpha-emitting targeted therapy, which can be valuable for researchers and healthcare professionals interested in the field. [Extracted from the article]